Bristol Myers Squibb (BMY) Total Non-Current Liabilities (2009 - 2026)

Bristol Myers Squibb (BMY) has 18 years of Total Non-Current Liabilities data on file, last reported at $61.5 billion in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 12.74% year-over-year to $61.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $61.5 billion (down 12.74% YoY) and the FY2025 annual result came in at $66.5 billion, down 7.33% from the prior year.
• Total Non-Current Liabilities declined to $61.5 billion in Q1 2026 per BMY's latest filing, from $66.5 billion in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $75.8 billion in Q1 2024 and bottomed at $55.6 billion in Q2 2023.
• The 5-year median for Total Non-Current Liabilities is $64.1 billion (2022), against an average of $65.0 billion.
• The widest annual swing landed in 2023, when Total Non-Current Liabilities decreased 13.03%; it then jumped 35.92% in 2024.
• Tracing BMY's Total Non-Current Liabilities over 5 years: stood at $59.1 billion in 2022, then climbed by 0.24% to $59.3 billion in 2023, then rose by 21.08% to $71.7 billion in 2024, then decreased by 7.33% to $66.5 billion in 2025, then fell by 7.47% to $61.5 billion in 2026.
• Per Business Quant, the three latest BMY Total Non-Current Liabilities figures stand at $61.5 billion (Q1 2026), $66.5 billion (Q4 2025), and $72.8 billion (Q3 2025).

Peer Comparison